Saint-Herblain (France), June 11, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announces today that it has terminated the liquidity agreement relating to its ordinary shares concluded with Oddo BHF and Natixis on June 25, 2018, as the liquidity of the Company’s securities has improved. The termination is effective as of today.

By A Silva